Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis

被引:35
作者
Xie, Tong [1 ]
Zhang, Zhening [1 ]
Zhang, Xiaotian [1 ]
Qi, Changsong [1 ]
Shen, Lin [1 ]
Peng, Zhi [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
immunotherapy; chemotherapy; PD-L1; cutoff value; gastric cancer; EFFICACY; SAFETY; COMBINATION; NIVOLUMAB; CHEMO;
D O I
10.3389/fonc.2021.646355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Immunotherapy dramatically changed the treatment landscape of gastric cancer in recent years. PD-L1 expression was proposed as a biomarker; however, the treatment strategy according to PD-L1 is still uncertain. Here, we aimed to find the appropriate cutoff value of PD-L1 expression for gastric cancer immunotherapy.</p> Methods We did a systematic electronic research of prospective clinical trials of gastric cancer immunotherapy across databases. Studies that provided subgroup analysis results stratified by PD-L1 expression were included. Objective response rate (ORR), disease control rate (DCR), hazard ratio (HR), and 95% confidential interval (CI) of progression-free survival (PFS) and overall survival (OS) at different PD-L1 cutoff values were extracted.</p> Results Twelve studies and 6,488 patients in total were finally included for pooled analysis. ORR in allover, PD-L1-negative, combined positive score (CPS) >= 1, CPS >= 5, and CPS >= 10 population was 10%, 3%, 13%, 20%, and 23%, respectively. Immune checkpoint inhibitor (ICI) monotherapy failed to show survival advantage in allover and PD-L1-negative patients. Single-agent ICI therapy prolonged OS (HR = 0.84, 95% CI: 0.74-0.96) but not PFS (HR = 1.38, 95% CI: 0.91-2.09) in PD-L1 CPS >= 1 patients. For combined immunotherapy, ORR in allover, PD-L1-negative, CPS >= 1, CPS >= 5, and CPS >= 10 population was 64%, 57%, 48%, 60%, and 58%, respectively. Allover population could gain survival benefit from combined immunotherapy based on the results from Checkmate-649. OS (HR = 0.81, 95% CI: 0.71-0.92) and PFS (HR = 0.77, 95% CI: 0.69-0.86) were significantly prolonged in PD-L1 CPS >= 1 patients receiving combined immunotherapy.</p> Conclusion Efficacy and survival advantages improved with PD-L1 CPS. CPS >= 1 was the cutoff value for ICI monotherapy to gain survival benefit. Combined immunotherapy prolonged PFS and OS in allover population but needs further study to confirm it.</p>
引用
收藏
页数:10
相关论文
共 22 条
  • [1] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
    Bang, Y. -J.
    Ruiz, E. Yanez
    Van Cutsem, E.
    Lee, K. -W.
    Wyrwicz, L.
    Schenker, M.
    Alsina, M.
    Ryu, M. -H.
    Chung, H. -C.
    Evesque, L.
    Al-Batran, S. -E.
    Park, S. H.
    Lichinitser, M.
    Boku, N.
    Moehler, M. H.
    Hong, J.
    Xiong, H.
    Hallwachs, R.
    Conti, I.
    Taieb, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (10) : 2052 - 2060
  • [2] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    [J]. GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [3] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
    Fuchs, Charles S.
    Doi, Toshihiko
    Jang, Raymond W.
    Muro, Kei
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia I.
    Shah, Manish A.
    Metges, Jean-Phillipe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V.
    Ohtsu, Atsushi
    Shitara, Kohei
    Geva, Ravit
    Bleeker, Jonathan
    Ko, Andrew H.
    Ku, Geoffrey
    Philip, Philip
    Enzinger, Peter C.
    Bang, Yung-Jue
    Levitan, Diane
    Wang, Jiangdian
    Rosales, Minori
    Dalal, Rita P.
    Yoon, Harry H.
    [J]. JAMA ONCOLOGY, 2018, 4 (05)
  • [4] Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
    Galon, Jerome
    Bruni, Daniela
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 197 - 218
  • [5] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
    Herbst, Roy S.
    Giaccone, Giuseppe
    de Marinis, Filippo
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos H.
    Morise, Masahiro
    Felip, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Zou, Wei
    Sandler, Alan
    Enquist, Ida
    Komatsubara, Kimberly
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    McCleland, Mark
    Mocci, Simonetta
    Jassem, Jacek
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) : 1328 - 1339
  • [6] Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China
    Huang, Jing
    Mo, Hongnan
    Zhang, Weilong
    Chen, Xuelian
    Qu, Dong
    Wang, Xi
    Wu, Dawei
    Wang, Xingyuan
    Lan, Bo
    Yang, Beibei
    Wang, Pei
    Zhang, Bo
    Yang, Qing
    Jiao, Yuchen
    Xu, Binghe
    [J]. CANCER, 2019, 125 (05) : 742 - 749
  • [7] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
    Janjigian, Yelena Y.
    Bendell, Johanna
    Calvo, Emiliano
    Kim, Joseph W.
    Ascierto, Paolo A.
    Sharma, Padmanee
    Ott, Patrick A.
    Peltola, Katriina
    Jaeger, Dirk
    Evans, Jeffry
    de Braud, Filippo
    Chau, Ian
    Harbison, Christopher T.
    Dorange, Cecile
    Tschaika, Marina
    Le, Dung T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2836 - +
  • [8] Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Xu, Xin
    Li, Ning
    Xiao, Cheng
    Wang, Huan
    Teng, Lisong
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Peng, Bo
    Shen, Lin
    Xu, Nong
    [J]. BMC CANCER, 2020, 20 (01)
  • [9] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Boku, Narikazu
    Satoh, Taroh
    Ryu, Min-Hee
    Chao, Yee
    Kato, Ken
    Chung, Hyun Cheol
    Chen, Jen-Shi
    Muro, Kei
    Kang, Won Ki
    Yeh, Kun-Huei
    Yoshikawa, Takaki
    Oh, Sang Cheul
    Bai, Li-Yuan
    Tamura, Takao
    Lee, Keun-Wook
    Hamamoto, Yasuo
    Kim, Jong Gwang
    Chin, Keisho
    Oh, Do-Youn
    Minashi, Keiko
    Cho, Jae Yong
    Tsuda, Masahiro
    Chen, Li-Tzong
    [J]. LANCET, 2017, 390 (10111) : 2461 - 2471
  • [10] Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
    Kawazoe, Akihito
    Yamaguchi, Kensei
    Yasui, Hisateru
    Negoro, Yuji
    Azuma, Mizutomo
    Amagai, Kenji
    Hara, Hiroki
    Baba, Hideo
    Tsuda, Masahiro
    Hosaka, Hisashi
    Kawakami, Hisato
    Oshima, Takashi
    Omuro, Yasushi
    Machida, Nozomu
    Esaki, Taito
    Yoshida, Kazuhiro
    Nishina, Tomohiro
    Komatsu, Yoshito
    Han, Shi R.
    Shiratori, Shinichi
    Shitara, Kohei
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 129 : 97 - 106